Document:

Warrant dated April 15, 2008

 Exhibit 10.2 
 Execution Copy 
 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (1) AN EFFECTIVE REGISTRATION STATEMENT COVERING SUCH
SECURITIES UNDER THE SECURITIES ACT AND ANY OTHER APPLICABLE SECURITIES LAWS, OR (2) AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 
 AmeriCredit Corp. 
 WARRANT 

 7,500,000 shares of Common Stock 
 April 15, 2008 
 This WARRANT (this “Warrant”) of AmeriCredit Corp., a Texas corporation
(the “Company”), is being issued pursuant to that certain Forward Purchase Commitment Agreement, dated as of April 15, 2008 (the “Note Agreement”), by and between the Company and Deutsche Bank Securities Inc.,
a Delaware corporation (the “Recipient”). 
 1. Issuance of Warrant. For value received, the Company hereby grants to the Recipient
and its permitted successors and assigns (collectively, the “Holder”) the right to purchase from the Company up to 7,500,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”)
(such shares underlying this Warrant, the “Warrant Shares”), at a per share purchase price equal to $12.01 (the “Exercise Price”), subject to the terms, conditions and adjustments set forth below in this Warrant.

 2. Expiration of Warrant. This Warrant shall expire at 5:00 PM, prevailing Eastern time, on April 15, 2015 (the “Expiration
Date”). 
 3. Exercise of Warrant. This Warrant shall be exercisable pursuant to the terms of this Section 3. 
 3.1 Manner of Exercise. 
 (a) This
Warrant may only be exercised by the Holder hereof on or prior to the Expiration Date, in accordance with the terms and conditions hereof, in whole or in part (but not as to fractional shares), during the Company’s normal business hours on any
day other than a Saturday or a Sunday or a day on which commercial banking institutions in New York, New York are authorized by law to be closed (a “Business Day”), by surrender of this Warrant to the Company at its office
maintained pursuant to Section 10.2(a) hereof, accompanied by a written exercise notice in the form attached as Exhibit A hereto (or a reasonable facsimile thereof) duly executed by the Holder, together with the payment of the
aggregate Exercise Price for the number of Warrant Shares purchased upon exercise of this Warrant. Upon surrender of this Warrant, the Company shall cancel this Warrant document and shall, in the event of partial exercise, replace it with a new
Warrant document in accordance with Section 3.3. Notwithstanding the foregoing, the Company shall not be required to issue a Warrant covering less than 1,000 shares of Common Stock. 

 (b) Except as provided for in Section 3.1(c) below, each exercise of this Warrant must be
accompanied by payment in full of the aggregate Exercise Price in cash, by cashier’s check or wire transfer of immediately available funds for the number of Warrant Shares being purchased by the Holder upon such exercise. 
 (c) The aggregate Exercise Price for the number of Warrant Shares being purchased may also, in the sole discretion of the Holder, be paid in full or in
part on a “cashless basis” at the election of the Holder in the form of Warrant Shares withheld by the Company from the Warrant Shares otherwise to be received upon exercise of this Warrant having an aggregate Fair Market Value on the date
of exercise equal to the aggregate Exercise Price of the Warrant Shares being purchased by the Holder. For purposes of this Warrant, the term “Fair Market Value” means with respect to a particular date, the volume weighted average
trading price of the Common Stock on and as reported by the principal securities exchange on which the Common Stock is then listed or admitted to trading for the ten (10) trading days immediately preceding such date, or, if the Common Stock is
not listed or admitted to trading on any securities exchange, as determined in good faith and in a commercially reasonable manner by resolution of the Board of Directors of the Company, based on the best information available to it. 
 For purposes of illustration of a cashless exercise of this Warrant under Section 3.1(c), the calculation of such exercise shall be as follows: 

X = Y (A-B)/A 
 where: 
 X = the number of Warrant Shares to be issued to the Holder (rounded up to the nearest whole share) 
 Y = the number of Warrant Shares with respect to which this Warrant is being exercised 
 A = the Fair Market Value of the Common Stock 
 B = the Exercise Price 
 (d) For purposes of Rule 144 and sub-section (d)(3)(x) thereof, it is intended, understood, and
acknowledged that such amount of Common Stock that is issued in exchange for non-cash consideration upon exercise of this Warrant and in accordance with Section 3.1(c) above shall be deemed to have been acquired at the time this Warrant
was issued. 
 3.2 When Exercise Effective. Each exercise of this Warrant shall be deemed to have been effected immediately prior to
the close of business on the Business Day on which this Warrant shall have been duly surrendered to the Company as provided in Sections 3.1 and 12 hereof, and, at such time, the Holder in whose name any certificate or certificates for
Warrant Shares shall be issuable upon exercise as provided in Section 3.3 hereof shall be deemed to have become the holder or holders of record thereof of the number of Warrant Shares purchased upon exercise of this Warrant. 

3.3 Delivery of Common Stock Certificates and New Warrant. As soon as reasonably practicable after each exercise of this Warrant, in whole or
in part, and in any event within ten (10) Business Days thereafter, the Company, at its expense (including the payment by it of any applicable issue taxes), will cause to be issued in the name of and delivered to the Holder hereof or, subject
to Sections 9 and 10 hereof, as the Holder (upon payment by the Holder of any applicable transfer taxes) may direct: 
 (a) a
certificate or certificates (with appropriate restrictive legends, as applicable) for the number of duly authorized, validly issued, fully paid and nonassessable Warrant Shares to which the Holder shall be entitled upon exercise; and 
  

 2 

 (b) in case exercise is in part only, a new Warrant document of like tenor, dated the date hereof, for
the remaining number of Warrant Shares issuable upon exercise of this Warrant after giving effect to the partial exercise of this Warrant. 
 3.4 Fractional Warrant Shares. The Company shall not be required to issue fractional Warrant Shares on the exercise of this Warrant. If any fraction of a Warrant Share would, except for the provisions of this Section 3.4,
be issuable on the exercise of this Warrant (or specified portion thereof), the Company shall round up such fractional share to the nearest whole share. 
 3.5 Compliance with Law. 
 (a) Notwithstanding anything in this Agreement to the contrary, in no event
shall a Holder be entitled to exercise this Warrant unless (i) a registration statement filed under the Securities Act of 1933, as amended (the “Securities Act”), in respect of the issuance of the Warrant Shares is then
effective or (ii) an exemption from the registration requirements is available under the Securities Act for the issuance of the Warrant Shares at the time of such exercise. 
 (b) If any shares of Common Stock required to be reserved for purposes of exercise of this Warrant require, under any other Federal or state law or
applicable governing rule or regulation of any national securities exchange, registration with or approval of any governmental authority, or listing on any such national securities exchange before such shares may be issued upon exercise, the Company
will at its own expense use its best efforts to cause such shares to be duly registered or approved by such governmental authority or listed on the relevant national securities exchange, as the case may be. 
 3.6 Limitations on Settlement by the Company. Notwithstanding anything herein to the contrary, in no event shall the Company be required to
deliver Warrant Shares in connection with the exercise of this Warrant in excess of 15,000,000 shares of Common Stock (the “Capped Number”). The Company represents and warrants that the Capped Number is equal to or less than the sum
of (a) the number of authorized but unissued shares of Common Stock and (b) the number of treasury shares, in each case, of the Company that are not reserved for future issuance in connection with transactions in the shares of the capital
stock of the Company (other than this Warrant) on the date of this Agreement (such shares, the “Available Shares”). In the event the Company shall not have delivered the full number of Warrant Shares, up to the Capped Number,
otherwise deliverable as a result of the Company not having sufficient authorized but unissued shares of capital stock available at the time or times that this Warrant is exercised (the resulting deficit, the “Deficit Shares”), the
Company shall be continually obligated to deliver, from time to time until the full number of Deficit Shares have been delivered pursuant to this paragraph, Warrant Shares when, and to the extent, that (i) shares of capital stock are
repurchased, acquired or otherwise received by the Company or any of its subsidiaries after the date of exercise of this Warrant (whether or not in exchange for cash, fair value or any other consideration), (ii) authorized and unissued shares
of capital stock reserved for issuance in respect of other transactions become no longer so reserved and (iii) the Company additionally authorizes any unissued shares of capital stock. The Company shall immediately notify Holder of the
occurrence of any of the foregoing events (including the number of shares of capital stock subject to clause (i), (ii) or (iii) and the corresponding number of shares of capital stock to be delivered) and promptly deliver such Warrant
Shares thereafter. The Company shall not take any action to decrease the number of Available Shares below the Capped Number. 
  

 3 

 4. Certain Adjustments. For so long as this Warrant is outstanding: 
 4.1 Mergers or Consolidations. If at any time after the date hereof, there shall be a capital reorganization (other than a combination or
subdivision of Common Stock otherwise provided for herein) resulting in a reclassification to or change in the securities issuable upon exercise of this Warrant (a “Reorganization”), or a merger or consolidation of the Company with
another corporation, partnership, limited liability company, or business organization (a “Person” or the “Persons”) (other than a merger with another Person in which the Company is a continuing corporation and which
does not result in any reclassification or change in the securities issuable upon exercise of this Warrant or a merger effected exclusively for the purpose of changing the domicile of the Company) (a “Merger”), then, as a part of
such Reorganization or Merger, lawful provision and adjustment shall be made so that the Holder shall thereafter be entitled to receive, upon exercise of this Warrant, the number of shares of stock or any other equity or debt securities or property
to which the Holder would have been entitled upon consummation of the Reorganization or Merger if such Holder had exercised this Warrant immediately prior to such Reorganization or Merger. In any such case, appropriate adjustment shall be made in
the application of the provisions of this Warrant with respect to the rights and interests of the Holder after the Reorganization or Merger to the end that the provisions of this Warrant (including adjustment of the Exercise Price then in effect and
the number of Warrant Shares) shall be applicable after that event, as near as reasonably may be, in relation to any shares of stock, securities, property or other assets thereafter deliverable upon exercise of this Warrant. The provisions of this
Section 4.1 shall similarly apply to successive Reorganizations and/or Mergers. The Company will not effect any Reorganization or Merger unless prior to the consummation thereof each corporation or entity (other than the Company) which
may be required to deliver any securities or other property upon the exercise of the Warrant as provided herein shall assume in a written agreement the obligation to deliver to the Holder such securities or other property as (in accordance with the
foregoing provisions) the Holder may be entitled to receive and agreeing and confirming that this Warrant shall continue in full force and effect, enforceable against the Company and such corporation or entity in accordance with the terms thereof
and hereof. The foregoing provisions of this Section 4.1 shall similarly apply to successive Reorganizations and Mergers. 
 4.2
Splits and Subdivisions; Dividends. In the event the Company should at any time or from time to time (a) effectuate a split or subdivision of the outstanding shares of Common Stock, (b) pay a dividend in or make a distribution
payable in additional shares of Common Stock or other securities that are convertible or exchangeable or exercisable into shares of Common Stock (“Common Stock Equivalents”), or (c) issue by reclassification of its Common Stock
any other capital stock of the Company, in each case without payment of any consideration by such holder for the additional shares of Common Stock or Common Stock Equivalents (including the additional shares of Common Stock issuable upon conversion
or exercise thereof), then, as of the applicable record date (or the date of such distribution, split, subdivision or reclassification if no record date is fixed), the per share Exercise Price shall be appropriately decreased and the number of
Warrant Shares shall be appropriately increased in proportion to such increase (or potential increase) of outstanding shares; provided, however, that no adjustment shall be made in the event the split, subdivision, dividend, distribution or
reclassification is not effectuated. The adjustment pursuant to this Section 4.2 shall be made successively each time that any event listed in this Section 4.2 above shall occur. 
 4.3 Combination of Shares. If the number of shares of Common Stock outstanding at any time after the date hereof is decreased by a combination or
reverse split of the outstanding shares of Common Stock, the per share Exercise Price shall be appropriately increased and the number of shares of Warrant Shares shall be appropriately decreased in proportion to such decrease in outstanding shares.

 4.4 Cash Dividends and Other Distributions. If, when the Exercise Price is greater than the Fair Market Value, the Company shall
distribute to holders of Common Stock (a) any dividend or other distribution of cash, evidences of its indebtedness, or any other properties or securities (other than any dividend or distribution described in Section 4.2) or
(b) any options, warrants, or other rights to subscribe 

  

 4 

 
for or purchase any of the foregoing (other than any rights, options, warrants, or securities described below), the Holder shall thereafter be entitled, in
addition to the Warrant Shares receivable upon exercise of the Warrant, to receive, upon the exercise of the Warrant, the same cash, evidences of indebtedness, other property or securities, or options, warrants or other rights to subscribe for or
purchase the foregoing that the Holder would have received if such Holder had exercised this Warrant immediately prior to such distribution. At the time of such distribution, the Company shall make appropriate reserves to ensure the timely
performance of the provisions of this Section 4.4; provided, however, that the Holder shall not be entitled to receive any of the foregoing upon the exercise of this Warrant (i) if, at the time of such distribution, the
Company makes the same distribution to the Holder of this Warrant as it makes to holders of Common Stock pro rata based on the number of shares of Common Stock for which this Warrant is exercisable (whether or not currently exercisable), or
(ii) as a result of the issuance or other sale by the Company of any of its shares of Common Stock upon (A) the conversion or exchange of any of the Company’s preferred stock, warrants, options or other convertible or exchangeable
securities, provided, such preferred stock, warrants, options or other convertible or exchangeable securities are outstanding as of the date of this Agreement, (B) the grant or exercise of any stock options, restricted stock, restricted
stock units, stock appreciation rights or other forms of stock or stock-based rights granted to officers, directors or employees of the Company pursuant to a stock option plan, benefit plan or incentive plan of the Company, whether in effect as of
the date of this Agreement or approved by the Board of Directors of the Company after the date of this Agreement, or (C) the grant or issuance of rights to holders of Common Stock pursuant to a rights offering. 
 4.5 Redemptions; Tender Offers; Exchange Offers. In the event that the Company or any subsidiary of the Company shall, directly or indirectly,
redeem, purchase or otherwise acquire shares of Common Stock pursuant to a plan of redemption, tender offer or exchange offer for a price per share of Common Stock that is greater than the Fair Market Value of a share of Common Stock (calculated as
of the end of the trading day on the day on which such tender offer or exchange offer expires), then the Exercise Price shall be adjusted to a number determined by multiplying the Exercise Price immediately before such redemption, acquisition or
exchange by a fraction of which the denominator shall be the then Fair Market Value per share of Common Stock immediately prior to such event and the numerator shall be the result of dividing (a) an amount equal to (i) the product of the
number of shares of Common Stock outstanding and the Fair Market Value per share of Common Stock, in each case immediately prior to such event minus (ii) the aggregate consideration paid by the Company in such event (plus, in the case of
such options, rights or convertible or exchangeable securities, the aggregate additional consideration to be paid by the Company upon exercise, conversion or exchange), by (b) the number of shares of Common Stock outstanding immediately after
such redemption, acquisition or exchange. 
 4.6 Certain Issuances. 
 (a) Without duplication of any other items contained in the Warrant, if at any time or from time to time the Company shall issue (i) Common Stock at
a price per share that is lower at the date of such issuance than the then current Fair Market Value or (ii) rights, options, or warrants for, or securities convertible or exchangeable into, Common Stock entitling the holders thereof to
subscribe for or purchase shares of Common Stock at a price per share that is lower at the date of such issuance than the then current Fair Market Value, then the number of shares of Common Stock thereafter purchasable upon the exercise of the
Warrant shall be determined by multiplying the number of shares of Common Stock theretofore purchasable upon exercise of the Warrant by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding on the date of
issuance of such Common Stock, rights, options, warrants, or convertible or exchangeable securities (assuming the exercise or conversion of all then outstanding rights, options, warrants or convertible or exchangeable securities) plus the number of
additional shares of Common Stock offered for subscription or purchase or into which such securities are convertible or exchangeable, and the denominator of which shall be the number of shares of Common 

  

 5 

 
Stock outstanding on the date of issuance of such Common Stock, rights, options, warrants, or convertible or exchangeable securities (assuming the exercise
or conversion of all then outstanding rights, options, warrants or convertible or exchangeable securities) plus the total number of shares of Common Stock that could be purchased with the aggregate consideration received through issuance of such
Common Stock, rights, options, warrants, or convertible or exchangeable securities at the then current Exercise Price. In the event of any such adjustment, the Exercise Price shall be adjusted to a number determined by dividing the Exercise Price
immediately before such date of issuance by the aforementioned fraction. Such adjustment shall be made whenever such shares of Common Stock, rights, options, warrants, or convertible or exchangeable securities are issued and shall become effective
retroactively immediately after the date on which such Persons became entitled to receive such shares of Common Stock, rights, options, warrants or convertible or exchangeable securities. 
 (b) This Section 4.6 shall not apply to issuances of Common Stock, rights, options, warrants, or convertible or exchangeable securities
resulting from or in connection with: 
 (i) an issuance of Common Stock, rights, warrants, options and/or convertible or exchangeable
securities in connection with any financing transaction, including, without limitation, senior or subordinated notes, securitizations or similar transactions, commercial bank or non-bank facilities, commitments or arrangements, bridge financing or
back-stop facilities, commitments or arrangements, whole-loan purchase facilities, commitments or arrangements, forward purchase facilities, commitments or arrangements, or other similar facilities, commitments, arrangements or issuances of debt
obligations or securities, 
 (ii) the conversion or exchange of any of the Company’s preferred stock, warrants, options or other
convertible or exchangeable securities, provided, such preferred stock, warrants, options or other convertible or exchangeable securities are outstanding as of the date of this Agreement or were issued in connection with a transaction set out
in Section 4.6(b)(i), 
 (iii) the grant or exercise of any stock options, restricted stock, restricted stock units, stock
appreciation rights or other forms of stock or stock-based rights granted to officers, directors or employees of the Company pursuant to a stock option plan, benefit plan or incentive plan of the Company, whether in effect as of the date of this
Agreement or approved by the Board of Directors of the Company after the date of this Agreement, 
 (iv) the exercise of the Warrant,

 (v) a Merger or Reorganization, 
 (vi) a bona fide firm commitment public offering of the Common Stock of the Company that is consummated more than ninety (90) days following the date hereof, where the issuance price for shares of Common Stock in such offering
is not more than 10% less than the closing sale price for the shares of Common Stock of the Company on the day that the issuance price in such offering is determined, on and as reported by the principal securities exchange on which the Common Stock
is then listed or admitted to trading, or 
 (vii) the grant or issuance of rights pursuant to a shareholder rights plan. 
 (c) If any Common Stock, rights, options, warrants or convertible or exchangeable securities are issued together with other obligations or securities,
then an allocation shall be made of the aggregate consideration received as between such Common Stock, rights, options, warrants or convertible or exchangeable securities, on the one hand, and such other obligations or securities, on the other hand
(as 

  

 6 

 
determined in good faith and in a commercially reasonable manner by the Board of Directors, whose determination shall be evidenced by a board resolution, a
copy of which will be sent to Holders upon request), to determine a price per share for such Common Stock, rights, options, warrants or convertible or exchangeable securities for the purposes of this Section 4.6. This
Section 4.6 shall apply with equal force and effect to any amendment, revision, adjustment, or other modification of the terms of any outstanding rights, options, or warrants for, or securities convertible or exchangeable into, Common
Stock if and to the extent that such amendment, revision, adjustment, or other modification has the effect of allowing the holders thereof to subscribe for or purchase shares of Common Stock at a price per share that is lower at the date of such
modification than the then current Fair Market Value, subject to the provisions of Section 4.6(b). No adjustment shall be made pursuant to this Section 4.6 that would have the effect of decreasing the number of shares of
Common Stock purchasable upon exercise of the Warrant or of increasing the Exercise Price. 
 4.7 Superseding Adjustment. Upon the
expiration of any rights, options, warrants, or conversion or exchange privileges that resulted in any adjustment pursuant to this Section 4, if any thereof shall not have been exercised, the number of Warrant Shares purchasable upon the
exercise of this Warrant shall be readjusted as if (a) the only shares of Common Stock issuable upon exercise of such rights, options, warrants, or conversion or exchange privileges were the shares of Common Stock, if any, actually issued upon
the exercise of such rights, options, warrants, or conversion or exchange privileges and (b) shares of Common Stock actually issued, if any, were issuable for the consideration actually received by the Company upon such exercise plus the
aggregate consideration, if any, actually received by the Company for the issuance, sale, or grant of all such rights, options, warrants, or conversion or exchange privileges whether or not exercised and the Exercise Price shall be readjusted
inversely; provided, however, that no such readjustment shall (except by reason of an intervening adjustment under Section 4.2) have the effect of either decreasing the number of Warrant Shares purchasable upon the exercise of
this Warrant or increasing the Exercise Price by an amount in excess of the amount of the adjustment to such number of Warrant Shares or to the Exercise Price initially made in respect of the issuance, sale, or grant of such rights, options,
warrants, or conversion or exchange privileges. 
 4.8 Notices of Record Date, Etc. In case: 
 (a) the Company shall take a record of the holders of its Common Stock (or other securities at the time receivable upon the exercise of the Warrant) for
the purpose of entitling them to receive any dividend or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities, or to receive any other right; 
 (b) of any Reorganization of the Company, any Merger of the Company with or into another corporation, or any conveyance of all or substantially all of
the assets of the Company to another corporation; or 
 (c) of any voluntary or involuntary dissolution, liquidation or winding up of the
Company, 
 then, and in each such case, the Company shall mail or cause to be mailed to the Holder specifying, as the case may be, (i) the date on
which a record is to be taken for the purpose of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (ii) the date on which such Reorganization, Merger, conveyance, dissolution,
liquidation or winding up is to take place, and the time, if any, which is to be fixed, as to which the holders of record of Common Stock (or such other securities at the time receivable upon the exercise of the Warrant) shall be entitled to
exchange their shares of Common Stock (or such other securities) for securities or other property deliverable upon such Reorganization, Merger, conveyance, dissolution, liquidation or winding up. Such notice shall be mailed at least ten
(10) days prior to the date therein specified and the Warrant may be exercised prior to said date during the term of the Warrant. 
  

 7 

 4.9 No Duplication. Notwithstanding anything else contained in this Section 4, no
single event shall result in an adjustment to either the Exercise Price or the number of Warrant Shares issuable upon exercise of the Warrant under more than one of the subsections set forth in this Section 4 so as to result in
duplication. 
 5. No Impairment. The Company will not, by amendment of its Articles of Incorporation or Bylaws or through any consolidation, merger,
reorganization, transfer of assets, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant. Without limiting the generality of the foregoing,
the Company will not take any action which results in any adjustment of the number of Warrant Shares if the total number of shares of Common Stock issuable after the action upon the exercise of this Warrant would exceed the Capped Number.

 6. Chief Financial Officer’s Report as to Adjustments. With respect to each adjustment pursuant to Section 4 of this Warrant, the
Company, at its expense, will promptly compute the adjustment or re-adjustment in accordance with the terms of this Warrant and cause its Chief Financial Officer to certify the computation (other than any computation of the fair value of property of
the Company, as the case may be) and prepare a report setting forth, in reasonable detail, the event requiring the adjustment or re-adjustment and the amount of such adjustment or re-adjustment, the method of calculation thereof and the facts upon
which the adjustment or re-adjustment is based, and the Exercise Price and the number of Warrant Shares or other securities purchasable hereunder after giving effect to such adjustment or re-adjustment, which report shall be sent by a commercial
overnight courier to the Holder. The Company will also keep copies of all reports at its office maintained pursuant to Section 10.2(a) hereof and will cause them to be available for inspection at the office during normal business hours
upon reasonable notice by the Holder or any prospective purchaser of the Warrant designated by the Holder thereof. 
 7. Reservation of Shares. The
Company shall, solely for the purpose of effecting the exercise of this Warrant, at all times during the term of this Warrant, reserve and keep available, free from preemptive rights, out of its authorized but unissued shares of Common Stock, such
number of its shares of Common Stock equal to the Capped Number. The Company hereby represents and warrants that all shares of Common Stock issuable upon exercise of this Warrant shall be duly authorized and, when issued and paid for upon exercise
in accordance with the terms of this Warrant, shall be validly issued, fully paid and nonassessable, and free of preemptive rights and free from all taxes, liens, charges and security interests with respect to the issuer thereof, other than
restrictions on transfer pursuant to this Warrant and applicable federal and state securities laws. The Company covenants that the transfer agent for the Common Stock (which may be the Company if it is acting as its own transfer agent) (the
“Transfer Agent”) and every subsequent transfer agent for the Company’s Common Stock will be irrevocably authorized and directed by the Company at all times to reserve such number of authorized shares as is consistent with the
provisions of this Section 7. The Company will keep a copy of this Warrant on file with the Transfer Agent, and will furnish such Transfer Agent a copy of all notices of adjustments and certificates related thereto which are transmitted
to each Holder pursuant to Section 6. 
 8. Registration and Listing. 
 8.1 Definitions. As used in this Section 8, the term “Registrable Securities” means any shares of Common Stock
issuable upon the exercise of this Warrant and any other securities issued to the Holder in exchange or substitution for such shares, until the date (if any) on which such shares or other securities may be sold immediately without registration
pursuant to Rule 144 promulgated pursuant to the 

  

 8 

 
Securities Act. As used in this Section 8, the term “Best Efforts” means the efforts that a prudent person desirous of achieving
a result would use in similar circumstances to ensure that such result is achieved as expeditiously as possible, but shall not be deemed to mean that the Company shall be required to endanger its financial viability. 
 8.2 Registration. 
 (a) The Company shall prepare and file with the United States Securities and Exchange Commission
(the “SEC”), as soon as practicable but no later than the 45th day following the date hereof (the “Filing Due
Date”), a Registration Statement for an offering to be made on a delayed or continuous shelf basis following the date of effectiveness covering the resale of the Registrable Securities by the Holder (the “Registration
Statement”) in accordance with the intended method or methods of distribution thereof. The Registration Statement shall be on Form S-3 under the Securities Act and, if the Company is a well known seasoned issuer, shall be an automatic shelf
registration statement (each within the meaning of Rule 405 under the Securities Act) or, if Form S-3 is not available, another appropriate form selected by the Company permitting registration of the resale of the Registrable Securities by the
Holder from time to time on a delayed or continuous shelf basis. The Company shall use its Best Efforts cause the Registration Statement to become effective pursuant to the Securities Act as soon as practicable. Notwithstanding the foregoing, if the
Company shall furnish to the Holder a certificate signed by the Chief Executive Officer or Chief Financial Officer of the Company stating that, in the good faith judgment of the Board of Directors of the Company, such registration, offering or use
would reasonably be expected to materially adversely affect or materially interfere with any bona fide and imminent material financing of the Company or any imminent material transaction under consideration by the Company or would require the
disclosure of information that has not been, and is not otherwise required to be, disclosed to the public, the premature disclosure of which would materially adversely affect the Company, the Company shall have the right to defer taking action with
respect to such filing for a period of not more than 90 days after the Filing Due Date. The Company shall not include in the Registration Statement any securities other than the Registrable Securities. The Holder may select the underwriters for any
underwritten offering of the securities pursuant to the Registration Statement, subject to the consent of the Company, not to be unreasonably withheld. 
 (b) The Registration Statement shall not be deemed to have become effective under the Securities Act (i) unless it has been filed and has been declared effective under the Securities Act by the SEC and remains
effective pursuant to the Securities Act with respect to the disposition of all Registrable Securities on a continuous shelf basis until all such Registrable Securities are sold or cease to be Registrable Securities, or (ii) if the offering of
the Registrable Securities pursuant to such Registration Statement is interfered with by any stop order, cease trade order, injunction or other order or requirement of the SEC or any other governmental agency, court or stock exchange, other than by
reason of some act or omission by the Holder. 
 (c) No Holder of Registrable Securities may participate in any underwritten registration
pursuant to a Registration Statement filed pursuant to the terms hereof unless such Holder (i) agrees to sell such Holder’s Registrable Securities on the basis provided in and in compliance with any underwriting arrangements,
(ii) completes and executes all customary questionnaires, powers of attorney, indemnities, underwriting agreements and other documents reasonably required under the terms of such underwriting arrangements, and (iii) furnishes to the
Company such information regarding such Holder and the distribution of such Registrable Securities as the Company may, from time to time, reasonably request in writing to comply with the Securities Act and other applicable law. The Company may
exclude from such registration the Registrable Securities of any Holder who fails to furnish such information within a reasonable time after receiving such request. 
  

 9 

 (d) Each Holder of Registrable Securities agrees by acquisition of such Registrable Securities that, upon
receipt of any notice from the Company of the happening of any event of the kind described in Section 8.3(f)(ii), (iii), (v), (vi) or (vii) hereof, such Holder will forthwith discontinue of such
Registrable Securities covered by the Registration Statement or prospectus (a “Blackout”) until such Holder’s receipt of the copies of the supplemented or amended prospectus contemplated by Section 8(g) hereof, or
until it is advised in writing (the “Advice”) by the Company that the use of the applicable prospectus may be resumed, and has received copies of any amendments or supplements thereto. In the event the Company shall give any such
notice, the period of time for which a Registration Statement is required hereunder to be effective shall be extended by the number of days during such periods from and including the date of the giving of such notice to and including the date when
each seller of Registrable Securities covered by such Registration Statement shall have received the Advice or the copies of the supplemented or amended prospectus contemplated by Section 8(g) hereof and in no event shall (i) any
Blackout (or series of Blackouts) persist for more than sixty (60) days, or (ii) the aggregate number of days the Holder shall be subject to Blackouts during any twelve-month period exceed ninety (90) days. 
 8.3 Registration Procedures. At its expense, the Company will: 
 (a) promptly notify the Holder of the effectiveness of the Registration Statement filed in accordance with this Section 8 and use its Best Efforts to prepare and file with the SEC such amendments and
supplements to such Registration Statement and the prospectus used in connection therewith as may be necessary to (i) keep such registration statement continuously effective and the prospectus included therein continuously effective and usable
for a period commencing on the date that such Registration Statement is initially declared effective by the SEC and ending on the Termination Date (as defined below), and (ii) comply with the provisions of the Securities Act with respect to the
disposition of all securities covered by such Registration Statement during such period in accordance with the intended methods of disposition by the sellers thereof set forth in the Registration Statement, as so amended or such prospectus as so
supplemented from time to time at the request of Holder, including any underwritten offering of Registrable Securities pursuant to the Registration Statement; provided, however, that (1) before filing the Registration Statement or any
amendment thereto, or any related prospectus or any amendment or supplement thereto (including documents that would be incorporated or deemed to be incorporated in any of the foregoing by reference) the Company will furnish to Holder, not more than
one counsel chosen by Holder (“Special Counsel”) and the managing underwriters, if any, copies of all such documents proposed to be filed, which documents will be subject to the review and comment of Holder, such Special Counsel and
such underwriters, and the Company will not file any such Registration Statement or amendment thereto or any prospectus or any supplement thereto (excluding such documents that, upon filing, will be incorporated or deemed to be incorporated by
reference therein) to which Holder or the managing underwriter, if any, shall reasonably object, and (2) the Company shall notify the Special Counsel and each seller of Registrable Securities of any stop order issued or threatened by the SEC
and use its Best efforts to take all action required to prevent the entry of such stop order or to remove it if entered; 
 (b) use its Best
Efforts to obtain the withdrawal of any order suspending the effectiveness of the Registration Statement, or the lifting of any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any
jurisdiction, as soon as reasonably practicable; 
 (c) if requested by the managing underwriters, if any, or Holder, (i) promptly
incorporate in an amended prospectus, prospectus supplement or post-effective amendment to the Registration Statement such information as the managing underwriters, if any, and Holder agree should be included therein as may be required by applicable
law, including in connection with any intended method of disposition by the sellers of securities covered by the Registration Statement, and (ii) make all required 

  

 10 

 
filings of such amended prospectus, prospectus supplement or post-effective amendment as soon as practicable after the Company has received notification of
the matters to be incorporated therein; provided, however, that the Company will not be required to take any actions under this Section 8.3(c) that are not, in the written opinion of counsel for the Company, in compliance with applicable law;

 (d) furnish to the Holder and each underwriter, if any, without charge, such number of copies of the Registration Statement, each
amendment and supplement thereto, the prospectus included in such Registration Statement (including each preliminary prospectus), each amendment and supplement thereto, and such other documents as such seller may reasonably request in order to
facilitate the disposition of the Registrable Securities owned by the Holder; 
 (e) register or qualify such Registrable Securities under
such other securities or blue sky laws of such jurisdictions as the Holder reasonably requests and do any and all other acts and things which the Holder deems reasonably necessary or advisable to enable the Holder to consummate the disposition in
such jurisdictions of the Registrable Securities owned by the Holder; provided, however, that the Company shall not be required to: (i) qualify generally to do business in any jurisdiction where it would not otherwise be required to
qualify but for this subparagraph; (ii) subject itself to taxation in any such jurisdiction where it is not already subject; or (iii) consent to general service of process in any such jurisdiction where it is not already subject thereto;

 (f) notify Holder and the managing underwriters, if any, promptly, and (if requested by any such Person) confirm such notice in writing,
(i) when a prospectus or any prospectus supplement or post-effective amendment has been filed, and, with respect to the Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the
SEC or any other federal or state governmental authority for amendments or supplements to the Registration Statement or any related prospectus or for additional information related thereto, (iii) of the issuance by the SEC or any other federal
or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose, (iv) if at any time the representations and warranties of the Company contained
in any agreement contemplated by Section 8(l) (including any underwriting agreement) cease to be true and correct in any material respect, if and only to the extent that such representations and warranties are continuing under such
agreement or if there is a continuing prospectus delivery requirement, (v) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable
Securities for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose, (vi) of the occurrence of any event that makes any statement made in the Registration Statement or any related prospectus or any
document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration Statement, any related Prospectus or any such document so that, in the case of the
Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading and, in the case of a Prospectus, it will
not contain any untrue statement of a material fact or omit to state any material fact required to be stated or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and (vii) of the
Company’s reasonable determination that a post-effective amendment to a Registration Statement would be appropriate; 
 (g) upon the
occurrence of any event contemplated by Section 8(f)(vi) or 8(f)(vii), prepare a supplement or post-effective amendment to each Registration Statement or a supplement to the related Prospectus or any document incorporated therein by reference
or file any other required document so that, as thereafter delivered to the purchasers of the Registrable Securities being sold thereunder, such Prospectus will not contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; 
  

 11 

 (h) immediately upon their issuance, use its Best Efforts to cause all such Registrable Securities
registered pursuant to the Registration Statement to be listed on each securities exchange on which similar securities issued by the Company are then listed; 
 (i) use its Best Efforts to cause any Registrable Securities covered by such registration statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable
the sellers thereof to consummate the disposition of such Registrable Securities; 
 (j) comply with all applicable rules and regulations of
the SEC and make generally available to its security holders earnings statements satisfying the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder (or any similar rule later promulgated) no later than no later than 40
calendar days after the end of any 12-month period (or 60 calendar days after the end of any 12-month period if such period is a fiscal year) (i) commencing at the end of any fiscal quarter in which Registrable Securities are sold to
underwriters in a firm commitment or best efforts underwritten offering, or (ii) if not sold to underwriters in such an offering, commencing on the first day of the first fiscal quarter of the Company, after the effective date of a Registration
Statement, which statements shall cover such 12- month period; 
 (k) as needed, (i) engage an appropriate transfer agent and provide
the transfer agent with printed certificates for the Registrable Securities in a form eligible for deposit with The Depository Trust Company and (ii) provide a CUSIP number for the Registrable Securities; 
 (l) enter into such customary agreements (including, in the event of an underwritten offering, an underwriting agreement in form, scope and substance as
is customary in underwritten offerings) and take all such other commercially reasonable and customary actions in connection therewith (including those reasonably requested by Holder or, in the event of an Underwritten Offering, those reasonably
requested by the managing underwriters) in order to facilitate the disposition of such Registrable Securities and in such connection, but only where an underwriting agreement is entered into in connection with an underwritten offering: (i) make
such representations and warranties to the underwriters with respect to the businesses of the Company and its subsidiaries, the Registration Statement, prospectus and documents incorporated by reference or deemed incorporated by reference therein,
if any, in each case, in form, substance and scope as are customarily made by issuers to underwriters in underwritten offerings and confirm the same if and when requested; (ii) obtain opinions of counsel to the Company and updates thereof,
which counsel and opinions (in form, scope and substance) shall be reasonably satisfactory to the managing underwriters, if any, addressed to each of the underwriters covering the matters customarily covered in opinions requested in underwritten
offerings and such other matters as may be reasonably requested by such underwriters; (iii) use its Best Efforts to obtain “comfort” letters and updates thereof from the independent certified public accountants of the Company (and, if
necessary, any other certified public accountants of any subsidiary of the Company or of any business acquired by the Company for which financial statements and financial data is, or is required to be, included in the Registration Statement),
addressed to each of the underwriters, such letters to be in customary form and covering matters of the type customarily covered in “comfort” letters in connection with underwritten offerings; (iv) cause the Company’s management
to be made available for, and assist in, the marketing and disposition of such Registrable Securities in the manner and to the extent reasonably requested by the underwriters including, without limitation, participation by management in customary
road shows, investor conferences and other similar presentations; and (v) deliver such documents and certificates as may be reasonably requested by the managing underwriters, if any, to 

  

 12 

 
evidence the continued validity of the representations and warranties of the Company and its subsidiaries made pursuant to clause (i) above and to
evidence compliance with any customary conditions contained in the underwriting agreement entered into by the Company. The foregoing actions will be taken in connection with each closing under such underwriting agreement as and to the extent
required thereunder; 
 (m) make available for reasonable inspection during normal business hours by a representative of Holder holding
Registrable Securities being sold, any underwriter participating in any disposition of Registrable Securities, and any attorney, accountant or other agent retained by Holder or representatives or any underwriter (each, an
“Inspector”), all financial and other records, pertinent corporate documents and properties of the Company and its subsidiaries, and cause the officers, directors and employees of the Company and its subsidiaries to supply all
information reasonably requested by any such Inspector in connection with such Registration Statement; 
 (n) keep Special Counsel advised as
to the initiation and progress of any registration under this Section 8; 
 (o) cooperate with each seller of Registrable Securities and
each underwriter participating in the disposition of such Registrable Securities and their respective counsel in connection with any filings required to be made with any stock exchanges or markets in which securities of the Company are listed or
quoted; and 
 (p) take all other steps reasonably necessary to effect the registration of the Registrable Securities contemplated hereby.

 8.4 Expenses. The Company shall pay all Registration Expenses (as defined below) relating to the registration and listing
obligations set forth in this Section 8. For purposes of this Warrant, the term “Registration Expenses” means: (a) all registration, filing and NASD fees, (b) all fees and expenses of complying with securities
or blue sky laws, (c) all printing expenses, (d) the fees and disbursements of counsel for the Company and of its independent public accountants, including the expenses of any special audits or “comfort” letters required by or
incident to such performance and compliance, (e) premiums and other costs of policies of insurance (if any) against liabilities arising out of the public offering of the Registrable Securities being registered, if the Company desires such
insurance, and (f) reasonable fees and expenses of Special Counsel. 
 8.5 Information Provided by Holders. The Holder shall
furnish to the Company such information as the Company may reasonably request in writing to enable the Company to comply with the provisions hereof in connection with any registration referred to in this Warrant. 
 8.6 Effectiveness Period. The Company shall use its Best Efforts to keep the Registration Statement effective under the Securities Act until the
date (the “Termination Date”) which is the earlier date of when (a) all Registrable Securities covered by such Registration Statement have been sold or (b) all Registrable Securities covered by such Registration Statement
may be sold immediately without registration under the Securities Act and without volume restrictions pursuant to Rule 144 under the Securities Act, as determined by counsel to the Company pursuant to a written opinion letter to such effect,
addressed and reasonably acceptable to the Company’s transfer agent and the affected holders of Registrable Securities. 
 8.7 Net
Cash Settlement. Notwithstanding anything herein to the contrary, in no event will the Holder be entitled to receive a net-cash settlement as liquidated damages in lieu of physical settlement in shares of Common Stock, regardless of whether the
Common Stock underlying this Warrant is registered pursuant to an effective registration statement; provided, however, that the foregoing will not preclude the Holder from seeking other remedies at law or equity for breaches by the Company of
its registration obligations hereunder. 
  

 13 

 8.8 Indemnification. 
 (a) The Company agrees to indemnify and hold harmless each Holder, each past Holder, each person, if any, who controls such Holder within the meaning of the Securities Act or the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and their respective affiliates, directors, officers, employees, representatives and agents (collectively, the “Indemnified Parties”) from and against any losses, claims, damages or
liabilities, joint or several, or any actions in respect thereof (including, but not limited to, any losses, claims, damages, liabilities or actions relating to purchases and sales of the Warrant Shares) to which each Indemnified Party becomes
subject under the Securities Act, the Exchange Act or otherwise, insofar as such losses, claims, damages, liabilities or actions arise out of or are based upon (1) any untrue statement or alleged untrue statement of a material fact contained in
a Registration Statement or prospectus or in any amendment or supplement thereto or in any preliminary prospectus relating to a Registration Statement, or that arise out of, or are based upon, the omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, and (2) any failure or alleged failure of the Company to comply with any applicable statute, rule or regulation in connection with the
Registration Statement or any offering contemplated thereby, and shall reimburse, as incurred, the Indemnified Parties for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim,
damage, liability or action in respect thereof; provided, however, that (i) the Company shall not be liable in any such case to the extent that such loss, claim, damage or liability arises out of or is based upon any untrue
statement or alleged untrue statement or omission or alleged omission made in a Registration Statement or prospectus or in any amendment or supplement thereto or in any preliminary prospectus relating to a Registration Statement in conformity with
written information pertaining to such Holder and furnished to the Company by or on behalf of such Holder specifically for inclusion therein and (ii) with respect to any untrue statement or omission or alleged untrue statement or omission made
in any preliminary prospectus relating to a Registration Statement, the indemnity agreement contained in this subsection (a) shall not inure to the benefit of any Holder from whom the person asserting any such losses, claims, damages or
liabilities purchased the Warrant Shares concerned, to the extent that a prospectus relating to such Registrable Securities was required to be delivered by such Holder under the Securities Act in connection with such purchase and any such loss,
claim, damage or liability of such Holder results from the fact that there was not sent or given to such person, at or prior to the written confirmation of the sale of such Warrant Shares to such person, a copy of the final prospectus if the Company
had previously furnished copies thereof to such Holder; provided, further, however, that this indemnity agreement will be in addition to any liability which the Company may otherwise have to such Indemnified Party. The Company shall also
indemnify underwriters, if any, and each person who controls such underwriters within the meaning of the Securities Act or the Exchange Act to the same extent as provided above with respect to the indemnification of the Indemnified Parties.

 (b) Each Holder, severally and not jointly, will indemnify and hold harmless the Company and each person, if any, who controls the Company
within the meaning of the Securities Act or the Exchange Act from and against any losses, claims, damages or liabilities or any actions in respect thereof, to which the Company or any such controlling person may become subject under the Securities
Act, the Exchange Act or otherwise, insofar as such losses, claims, damages, liabilities or actions arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained in a Registration Statement or
prospectus or in any amendment or supplement thereto or in any preliminary prospectus relating to a Registration Statement, or arise out of or are based upon the omission or alleged omission to state therein a material fact necessary to make the
statements therein not misleading, but in each case only to the extent that the untrue statement or omission or alleged untrue statement or omission 

  

 14 

 
was made in conformity with written information pertaining to such Holder and furnished to the Company by or on behalf of such Holder specifically for
inclusion therein; and, subject to the limitation set forth immediately preceding this clause, shall reimburse, as incurred, the Company and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act
for any legal or other expenses reasonably incurred by the Company or any such controlling person in connection with investigating or defending any loss, claim, damage, liability or action in respect thereof. This indemnity agreement will be in
addition to any liability which such Holder may otherwise have to the Company or any of its controlling persons. Each Holder shall also provide customary indemnities to underwriters and each person who controls any of such underwriters within the
meaning of the Securities Act or the Exchange Act to the same extent as provided above with respect to the indemnification of the Company. 
 (c) Promptly after receipt by an indemnified party under this Section 8.8 of notice of the commencement of any action or proceeding (including a governmental investigation), such indemnified party will, if a claim in respect
thereof is to be made against the indemnifying party under this Section 8.8, notify the indemnifying party of the commencement thereof; but the omission so to notify the indemnifying party will not, in any event, relieve the indemnifying
party from any obligations to any indemnified party other than the indemnification obligation provided in subsection (a) or (b) above. In case any such action is brought against any indemnified party, and it notifies the indemnifying party
of the commencement thereof, the indemnifying party will be entitled to participate therein and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably
satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof the indemnifying party will not be liable to such indemnified party under this
Section 8.8 for any legal or other expenses. An indemnifying party that elects not to assume the defense in any such action brought against an indemnified party shall not be under an obligation to pay the fees and expenses of more than
one counsel for all parties. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened action in respect of which any indemnified party is or could have been a party
and indemnity could have been sought hereunder by such indemnified party unless such settlement includes an unconditional release of such indemnified party that is reasonably satisfactory to such indemnified party from all liability on any claims
that are the subject matter of such action, and does not include a statement as to or an admission of fault. 
 (d) If the indemnification
provided for in this Section 8.8 is unavailable or insufficient to hold harmless an indemnified party under subsections (a) or (b) above, then each indemnifying party shall contribute to the amount paid or payable by such
indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to in subsection (a) or (b) above (i) in such proportion as is appropriate to reflect the relative benefits received
by the indemnifying party or parties on the one hand and the indemnified party on the other from the sale of the Warrant Shares, pursuant to the Registration Statement, or (ii) if the allocation provided by the foregoing clause (i) is not
permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the indemnifying party or parties on the one hand and the indemnified
party on the other in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities (or actions in respect thereof) as well as any other relevant equitable considerations. The relative fault of the parties
shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party on the
one hand and the indemnified party on the other, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid by an indemnified party as a result of the
losses, claims, damages or liabilities referred to in the first sentence of this subsection (d) shall be deemed to include any legal or other expenses reasonably incurred by such 

  

 15 

 
indemnified party in connection with investigating or defending any action or claim which is the subject of this subsection (d). Notwithstanding any
other provision of this subsection (d), the Holders of the Registrable Securities shall not be required to contribute any amount in excess of the amount by which the net proceeds received by such Holders from the sale of the Warrant Shares, net
of the Exercise Price, pursuant to a Registration Statement exceeds the amount of damages which such Holders have otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this subsection (d),
each person, if any, who controls such indemnified party within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such indemnified party and each person, if any, who controls the Company within the
meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as the Company. 
 (e) The agreements contained
in this Section 8.8 shall survive the sale of the Warrant Shares pursuant to a Registration Statement and shall remain in full force and effect, regardless of any termination or cancellation of this Warrant or any investigation made by
or on behalf of any indemnified party. 
 9. Restrictions on Transfer. 
 9.1 Notice of Proposed Transfer. Prior to any transfer of any securities which are not registered under an effective registration statement under the Securities Act (“Restricted Securities”),
which transfer may only occur if there is an exemption from the registration provisions of the Securities Act and all other applicable securities laws, the Holder shall give written notice to the Company of the Holder’s intention to effect a
transfer. The following provisions shall apply to any proposed transfer of Restricted Securities: 
 (a) If in the opinion of counsel for the
Holder reasonably satisfactory to the Company the proposed transfer may be effected without registration of the Restricted Securities under the Securities Act, the Holder shall thereupon be entitled to transfer the Restricted Securities in
accordance with the terms of the notice delivered by the Holder to the Company. Each certificate representing the Restricted Securities issued upon or in connection with any transfer shall bear the restrictive legends required by
Section 9.2 hereof. 
 (b) If the opinion called for in (a) above is not delivered, the Holder shall not be entitled to
transfer the Restricted Securities until either: (i) receipt by the Company of a further notice from such Holder pursuant to the foregoing provisions of this Section 9.1 and fulfillment of the provisions of clause (i) above, or
(ii) such Restricted Securities have been effectively registered under the Securities Act. 
 9.2 Restrictive Legends. This
Warrant, each Warrant issued upon transfer or in substitution for this Warrant pursuant to Section 10 hereof, each certificate for Common Stock issued upon the exercise of the Warrant and each certificate issued upon the transfer of any
such Common Stock shall be (a) transferable only upon satisfaction of the conditions specified above and (b) stamped or otherwise imprinted with a legend reflecting the restrictions on transfer required under the Securities Act or other
applicable securities laws. 
 9.3 Termination of Restrictions. The restrictions imposed by this Section 9 upon the
transferability of Restricted Securities shall cease and terminate as to any particular Restricted Securities: (a) which shall have been effectively registered under the Securities Act, or (b) when, in the opinions of 

  

 16 

 
both counsel for the Holder and counsel for the Company, such restrictions are no longer required in order to insure compliance with the Securities Act or
Section 10 hereof. Whenever such restrictions shall cease and terminate as to any Restricted Securities, the Holder thereof shall be entitled to receive from the Company, without expense (other than applicable transfer taxes, if any),
new securities of like tenor not bearing the applicable legends required by Section 9.1 hereof or otherwise. 
 10. Ownership, Transfer, Sale
and Substitution of Warrant. 
 10.1 Ownership of Warrant. The Company may treat any Person in whose name this Warrant is
registered in the Warrant Register maintained pursuant to Section 10.2(b) hereof as the owner and holder thereof for all purposes, notwithstanding any notice to the contrary, except that, if and when any Warrant is properly assigned in
blank, the Company may (but shall not be obligated to) treat the bearer thereof as the owner of such Warrant for all purposes, notwithstanding any notice to the contrary. Subject to Sections 9 and 10 hereof, this Warrant, if properly
assigned, may be exercised by a new holder without a new Warrant first having been issued. 
 10.2 Office; Exchange of Warrant.

 (a) The Company will maintain its principal office or at such other offices as set forth in the Company’s most current filing (as of
the date notice is to be given) under the Exchange Act or as the Company otherwise notifies the Holder. 
 (b) The Company shall cause to be
kept at its office maintained pursuant to Section 10.2(a) hereof a Warrant Register for the registration and transfer of the Warrant. The name and address of the holder of the Warrant, the transfers thereof and the name and address of
the transferee of the Warrant shall be registered in such Warrant Register. The Person in whose name the Warrant shall be so registered shall be deemed and treated as the owner and holder thereof for all purposes of this Warrant, and the Company
shall not be affected by any notice or knowledge to the contrary. 
 (c) Upon the surrender of this Warrant, properly endorsed, for
registration of transfer or for exchange at the office of the Company maintained pursuant to Section 10.2(a) hereof, the Company at its expense will (subject to compliance with Section 9 hereof, if applicable) execute and
deliver to or upon the order of the Holder thereof a new Warrant of like tenor, in the name of such holder or as such holder (upon payment by such holder of any applicable transfer taxes) may direct, calling in the aggregate on the face thereof for
the number of shares of Common Stock called for on the face of the Warrant so surrendered (after giving effect to any previous adjustment(s) to the number of Warrant Shares). 
 10.3 Replacement of Warrant. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this
Warrant and, in the case of any such loss, theft or destruction of this Warrant, upon delivery of indemnity reasonably satisfactory to the Company in form and amount or, in the case of any mutilation, upon surrender of this Warrant for cancellation
at the office of the Company maintained pursuant to Section 10.2(a) hereof, the Company, at its expense, will execute and deliver, in lieu thereof, a new Warrant of like tenor and dated the date hereof. 
 10.4 Opinions. In connection with the sale of the Warrant Shares by the Holder, the Company agrees to cooperate with the Holder, and at the
Company’s expense, have its counsel provide any legal opinions required to remove the restrictive legends from the Warrant Shares in connection with a sale, transfer or legend removal request of Holder. 
 11. No Rights or Liabilities as Shareholder. No Holder shall be entitled to vote or receive dividends or be deemed the holder of any shares of Common Stock or any
other securities of the Company which 

  

 17 

 
may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the Holder, as such, any
of the rights of a shareholder of the Company or any right to vote for the election of directors or upon any matter submitted to shareholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any
recapitalization, issuance of stock, reclassification of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until the Warrant
shall have been exercised and the shares of Common Stock purchasable upon the exercise hereof shall have become deliverable, as provided herein. The Holder will not be entitled to share in the assets of the Company in the event of a liquidation,
dissolution or the winding up of the Company. 
 12. Notices. Any notice or other communication in connection with this Warrant shall be given in
writing and directed to the parties hereto as follows: (a) if to the Holder, to the attention of the Securitized Products Group, 60 Wall Street, New York, NY 10005; or (b) if to the Company, to the attention of its Chief Financial Officer
at its office maintained pursuant to Section 10.2(a) hereof; provided, that the exercise of the Warrant shall also be effected in the manner provided in Section 3 hereof. Notices shall be deemed properly delivered and
received when delivered to the notice party (i) if personally delivered, upon receipt or refusal to accept delivery, (ii) if sent via facsimile, upon mechanical confirmation of successful transmission thereof generated by the sending
telecopy machine, (iii) if sent by a commercial overnight courier for delivery on the next Business Day, on the first Business Day after deposit with such courier service, or (iv) if sent by registered or certified mail, five
(5) Business Days after deposit thereof in the U.S. mail. 
 13. Payment of Taxes. The Company will pay all taxes and other governmental charges
attributable to the issuance of shares of Common Stock underlying this Warrant upon exercise of this Warrant; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in
the transfer or registration of this Warrant or any certificate for shares of Common Stock underlying this Warrant in a name other than of the Holder. The Holder is responsible for all other tax liability that may arise as a result of holding or
transferring this Warrant or receiving shares of Common Stock underlying this Warrant upon exercise hereof. 
 14. Miscellaneous. This Warrant and any
term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the change, waiver, discharge or termination is sought. This Warrant shall be construed and enforced in
accordance with and governed by the laws of the State of Texas. The section headings in this Warrant are for purposes of convenience only and shall not constitute a part hereof. Each of the Company and the Holder hereby irrevocably and
unconditionally submits, for itself and its property, to the exclusive jurisdiction of any New York State court or Federal court of the United States of America sitting in New York City, and any appellate court from any thereof, in any action or
proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect to any such action or proceeding may
be heard and determined in such New York State or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in the any other manner provided by law. Each of the Company and the Holder hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection that it may
now or hereafter have to the laying of venue of any suit, action, or proceeding arising out of or relating to this Agreement in any New York State or Federal court sitting in New York City. Each of the parties hereto hereby irrevocably waives, to
the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 
 [Signature Page Follows] 
  

 18 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the date first above written.

  

			
	AMERICREDIT CORP.
		
	By:	 	  

	Name:	 	Chris A. Choate
	Title:	 	Chief Financial Officer

  

 19 

 EXHIBIT A 
 FORM OF EXERCISE NOTICE 
 [To be executed only upon exercise of Warrant] 
 To AmeriCredit Corp.: 
 The undersigned registered holder of the within
Warrant hereby irrevocably exercises the Warrant pursuant to Section 3.1 of the Warrant with respect to                      Warrant
Shares, at an exercise price per share of $12.01, and requests that the certificates for such Warrant Shares be issued, subject to Sections 9 and 10 of the Warrant, in the name of, and delivered to: 
  

			
	  
	  	
	  
	  	
	  
	  	
	  
	  	

 The undersigned is hereby making payment for the Warrant Shares in the following manner: [check one] 

 ̈ by cash in accordance with Section 3.1(b) of the Warrant 
  ̈ via cashless exercise in accordance with Section 3.1(c) of the Warrant 
 The
undersigned hereby represents and warrants that it is, and has been since its acquisition of the Warrant, the record and beneficial owner of the Warrant. 
 Dated:                      
  

					
	  
	 		 	
	Print or Type Name	 		 	
			
	  
	 		 	
	(Signature must conform in all respects to name of holder as specified on the face of Warrant)
			
	  
	 		 	
	(Street Address)	 		 	
			
	  
	 		 	
	(City) (State) (Zip Code)	 		 	

  

 A-1Letter Agreement

 EXHIBIT 10.1 
 April 15, 2008 
 Ms. Elissa J. Lindsoe 
  
  
  
 Dear Elissa: 
 This letter describes our mutual agreement regarding your employment with Urologix, Inc. (“Urologix”). 
  

	1.	You hereby resign as Chief Financial Officer as of the date of this letter agreement. Your status as “executive officer” of Urologix and as its principal financial
officer/principal accounting officer will cease as of the date of this letter agreement. 

  

	2.	Your employment with Urologix will terminate as of May 6, 2008. Beginning May 7, 2008, Urologix will pay you severance by continuing to pay your base salary (excluding
bonus) in accordance with Urologix’ regular payroll practices for a period that will end the earliest of (a) November 7, 2008; (b) the date on which you secure other full-time employment; (c) the date on which you secure
other part-time employment in which you would be considered an “exempt employee” under the Fair Labor Standards Act; (d) the date on which you breach any provision of this letter agreement or the Non-Compete Agreement as described
below; or (e) the date on which the aggregate amount paid in severance and the employer portion of the cost of COBRA continuation coverage as provided in paragraph 4 below equals $95,000 (the period from May 7, 2008 to such earliest date
shall be defined herein as the “Severance Period”). With the first payroll following May 6, 2008, you will receive a single lump-sum payment equal to any accrued unused vacation time due you under the Company’s vacation policy.

  

	3.	The Letter Agreement related to severance and change in control matters dated September 29, 2006 will become null and void and will be superseded by this letter agreement after
the date hereof, provided that the Agreement Regarding Employment, Inventions, Confidential Information and Non-Competition that you signed in connection with that Letter Agreement and dated September 29, 2006 (the
“Non-Compete Agreement”) will remain in full force and effect. 

  

	4.	 After termination of your employment in accordance with paragraph 2, you may continue health and certain other insurance coverages according to state and federal
law (COBRA) beginning June 1, 2008 for up to eighteen months or until you become covered through another group plan, in which case your COBRA eligibility will end. Following termination of your employment in accordance with paragraph 2, you
will receive a notice detailing your rights to continue insurance coverage under COBRA. You will be responsible for the full cost of the COBRA continuation coverage; provided, however, during the Severance Period, Urologix shall pay
the employer’s portion of the cost of 

  

 Page 1 of 4 

	 	 
COBRA continuation coverage. Once your COBRA eligibility expires, you will have the option of exercising your “Individual Conversion Right” to
receive coverage through an individual plan with Urologix’ health plan provider, or you may apply for an individual policy. 

  

	5.	This letter agreement does not affect the terms of any stock option granted to you by Urologix, with the terms relating to vesting, exercisability and all other matters in
accordance with the provisions of the option agreements relating to such options. 

  

	6.	Urologix agrees that it will not, directly or indirectly, make any derogatory comments to any person or entity about you. Urologix may state your focus on personal matters as the
reason for your resignation. 

 In consideration for these benefits: 
  

	1.	You hereby release, agree not to sue and forever discharge Urologix, its past and present affiliates, officers, directors, agents, shareholders, employees, insurers, indemnitors,
successors or assigns (collectively, the “Releasees”) from any and all claims and causes of action, known or unknown, which you may have against any and all of them. Through this release, you extinguish all causes of action against the
Releasees occurring up to the date on which you sign this letter agreement including, but not limited to, any contract, commission, wage or benefit claims; intentional infliction of emotional distress, defamation or any other tort claims; and all
claims arising from any federal, state or municipal law or ordinance, including the Employee Retirement Income Security Act and the Family Medical Leave Act. This release extinguishes any potential claims of discrimination arising from your
employment with Urologix and termination of that relationship, including specifically any claims under the Minnesota Human Rights Act, the Americans With Disabilities Act, Title VII of the Civil Rights Act of 1964, the Older Workers Benefit
Protection Act and the Age Discrimination in Employment Act. This release does not extinguish any claims which arise against any Releasee after you sign this letter agreement and does not extinguish any claims for payments required under this letter
agreement. You certify that you (a) have not filed any claims, complaints or other actions against any Releasee; and (b) are hereby waiving any right to recover from any Releasee under any lawsuit or charge filed by you or any federal,
state or local agency on your behalf based upon any event occurring up to the date on which you sign this letter agreement. You are advised by Urologix to review your rights and responsibilities under this letter agreement with your own lawyer.

  

	2.	On your last day of employment with Urologix, for no additional consideration provided to you other than the benefits provided herein, you will execute and deliver to Urologix a
further release of claims in the form of Exhibit A attached hereto. 

  

	3.	You have 21 days to review and consider this letter agreement. If you sign this letter agreement before 21 days have elapsed from the date on which you first receive it, then you
will be voluntarily waiving your right to the full 21-day review period. 

  

 Page 2 of 4 

	4.	After signing this letter agreement, you have the right to rescind the release insofar as it extends to your release of claims under the Age Discrimination in Employment Act and the
Minnesota Human Rights Act within 15 calendar days of the date upon which you sign this letter agreement. You understand that if you desire to rescind the release as provided above, you must put the rescission in writing and deliver it to Mitchell
Dann, Urologix, Inc., 14405 Twenty-First Avenue North, Minneapolis, MN 55447, by hand or by mail, within the required period. If you deliver the rescission by mail, it must be postmarked within the required period, properly addressed to Mitchell
Dann and sent by certified mail, return receipt requested. If you effectively exercise this rescission right, Urologix may, at its option, either nullify this letter agreement or keep it in effect in all respects other than as to your release of
claims that you have rescinded. If Urologix chooses to nullify this letter agreement, neither you nor Urologix will have any further obligation to the other under this letter agreement. 

  

	5.	You certify that you have returned all of Urologix’ property in your possession. 

  

	6.	You agree that you will not, directly or indirectly, make any derogatory comments to any person or entity about Urologix, its past and present affiliates, officers, directors,
agents, shareholders and employees, or in any way interfere with or attempt to damage any of Urologix’ business or employment relationships. 

  

	7.	You agree to abide by the terms and conditions of the Non-Compete Agreement and agree that Urologix may, in addition to other remedies provided under the Non-Compete Agreement,
withhold payments due to you under this letter agreement for violation of the Non-Compete Agreement. You also agree that the benefits provided under this letter agreement provide further and sufficient consideration for your obligations under the
Non-Compete Agreement. 

 This letter agreement and offer of benefits to you shall not in any way be construed as an admission of liability by
Urologix or as an admission that Urologix has acted wrongfully with respect to you. Urologix specifically denies and disclaims any such liability or wrongful acts. 
 In the event that any provision of this letter agreement is found to be illegal or unenforceable, such provision will be severed or modified to the extent necessary to make it enforceable and, as so severed or modified, the remainder of
this letter agreement shall remain in full force and effect. This letter agreement shall be binding upon the successors and assigns of Urologix, whether pursuant to merger, exchange or sale of all or substantially all of the assets of Urologix and
such successor shall assume Urologix’ obligations hereunder. 
 By signing this letter agreement, you agree that you have entered into it voluntarily,
without coercion, duress or reliance on any representations by any Urologix employee, agent or lawyer. 
  

 Page 3 of 4 

 If this letter agreement accurately reflects our understanding and agreement, please sign the original and copy and
return the original to me. The copy is for your file. 
  

	
	Sincerely,
	
	UROLOGIX, INC.
	
	/s/ Mitchell Dann
	By: Mitchell Dann
	        Interim Chief Executive Officer
	
	Read and agreed to, this 15th day of April, 2008.
	
	/s/ Elissa J. Lindsoe
	Elissa J. Lindsoe

  

 Page 4 of 4 

 EXHIBIT A 
 TO 
 LETTER AGREEMENT 
                     , 2008 
 Mitchell Dann 
 Urologix, Inc. 
 14405 Twenty-First Avenue North 
 Minneapolis, MN 55447 
 Dear Mr. Dann: 
 I, the undersigned, in consideration of the benefits provided in that letter agreement from Urologix, Inc.
(“Urologix”) to me dated April 15, 2008 (the “Agreement”), hereby release, agree not to sue, and forever discharge Urologix, , its past and present affiliates, officers, directors, agents, shareholders, employees, insurers,
indemnitors, successors or assigns (collectively the “Releasees”), from any and all manner of claims, demands, actions, causes of action, administrative claims, liability, damages, claims for punitive or liquidated damages, claims for
attorneys’ fees, costs and disbursements, individual or class action claims, or demands of any kind whatsoever, I have or might have against them or any of them, whether known or unknown, in law or equity, contract or tort, arising out of or in
connection with my employment with Urologix, or the separation of that employment, or otherwise, and however originating or existing, from April 15, 2008 through the date of this release. 
 This release includes any claims I may have for wages, bonuses, deferred compensation, vacation pay, separation pay and/or benefits, defamation, improper discharge
(based on contract, common law, or statute, including any federal, state or local statute or ordinance prohibiting discrimination or retaliation in employment), the Minnesota Human Rights Act, Title VII of the Civil Rights Act of 1964 as amended,
the Americans with Disabilities Act, the Older Workers Benefit Protection Act and the Age Discrimination in Employment Act, and any claim for discrimination or retaliation based on a protected class under state or federal law. I hereby waive any and
all relief not provided for in this release. 
 I affirm that I have not caused or permitted, and to the full extent permitted by law will not cause or
permit to be filed (to the extent that I am able to control such filing), any charge, complaint, or action of any nature or type against the Releasees, including but not limited to any action or proceeding raising claims arising in tort or contract,
or any claims arising under federal, state or local laws, including discrimination law. 
 I understand that I may rescind this release within seven
(7) calendar days after signing it to reinstate claims under the Age Discrimination in Employment Act and fifteen (15) calendar days after signing it to reinstate claims arising under the Minnesota Human Rights Act. In order to be
effective, the rescission must (a) be in writing; and (b) delivered to Mitchell Dann, Urologix, Inc., 14405 Twenty-First Avenue North, Minneapolis, MN 55447, by hand or by mail, within the required period; and (c) if delivered by
mail, the rescission must be postmarked within the 

  

 A-1 

 
required period, properly addressed to Mitchell Dann and sent by certified mail, return receipt requested. I understand that any rescission of this release
shall not rescind or otherwise affect the release of claims contained in the Agreement and shall only reinstate claims as provided above arising from and after the date of the Agreement to the date of this release. This release will be effective
upon the expiration of the required period without rescission. I understand that if I rescind this release or the Agreement I will not continue to receive the benefits described in the Agreement. 
  

	
	Very truly yours,
	
	Elissa J. Lindsoe

  

 A-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}]]